key: cord-0690927-kog6v659
authors: Aiano, Felicity; Campbell, Colin; Saliba, Vanessa; Ramsay, Mary Elizabeth; Ladhani, Shamez N
title: COVID-19 vaccine given to children with comorbidities in England, December 2020–June 2021
date: 2021-11-05
journal: Arch Dis Child
DOI: 10.1136/archdischild-2021-323162
sha: 0f1766528fad12e63b6cb4cb14f330e78988f727
doc_id: 690927
cord_uid: kog6v659

nan

Children have been relatively spared by SARS-CoV-2 compared with adults. Most children remain asymptomatic or develop mild, transient illness. Severe COVID-19 requiring hospitalisation is rare in children, 1 and fatalities are even rarer. 2 During the first pandemic wave, children with severe neurodisabilities were identified as having the highest risk of severe and fatal COVID-19. 3 Consequently, the UK Joint Committee on Vaccination and Immunisation recommended COVID-19 vaccination for children aged ≥12 years with severe neurodisabilities who were more likely to be at higher risk of recurrent respiratory infections and spend time in specialised residential care settings for complex needs (https://www.gov.uk/ government/publications/covid-19-thegreen-book-chapter-14a). This recommendation was made in December 2020 at the same time as recommendations for adults with underlying comorbidities, even though COVID-19 vaccines were not authorised for individuals aged 12-15 years at the time, because the benefits of vaccination were assessed to outweigh potential harms.

To assess how well these recommendations were implemented in children, we analysed COVID-19 vaccination data from the National Immunisation Management System (NIMS) in children aged <16 years during December 2020-June 2021. NIMS is a near-real time online database of individual-level COVID-19 vaccination records in England. We sent questionnaires to general practitioners of 748 children recorded to have been vaccinated in NIMS to confirm their vaccination status, date and brand of vaccine, reason for vaccination, medical attendance post-vaccination and previous SARS-CoV-2 infection status; 598 (80%) returned the questionnaire, and 533 children were confirmed as receiving ≥1 COVID-19 vaccine dose. four received mixed doses (AstraZeneca then Pfizer-BioNTech). Only 2% (11/533) had medically attended side-effects postfirst dose, predominantly headaches and fever/fatigue/flu-like symptoms (7/533, 1%), with a similar proportion postsecond dose (8/533, 2%), mainly fever (6/8, 75%).

Only 47% (249/533) were appropriately vaccinated according to national recommendations, although 45 (8%) others, including 29 children with Down syndrome, likely also fulfilled the recommendation criteria (table 1). Such small numbers of vaccinated children, however, indicate that a large number of very highrisk children (eg, there are ~15 000 children aged 12-15 years with life-limiting conditions in England) have remained unprotected for >9 months. 4 Possible reasons include clinicians being cautious about prescribing an unauthorised vaccine or, alternatively, there may have been operational difficulties in arranging vaccination for children with appropriately trained staff at COVID-19 vaccine centres set up primarily for adult vaccination. Parents may also have been concerned about unauthorised vaccine use for their children.

Ten per cent (54/533) of children were vaccinated because they were immunosuppressed or they were household contacts of a vulnerable individual, although this recommendation was not made until 19 July 2021, while 20% (108/533) had comorbidities that were not eligible for vaccination (table 1) . Presumably, clinicians considered the benefits of vaccination to outweigh potential risks for these children.

On 13 September 2021, the UK announced COVID-19 vaccination for all individuals aged 12-15 years. However, a multidisciplinary approach, including flexible vaccination services with appropriately trained staff, will be critical for ensuring high vaccine uptake in children with complex needs. 

Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS

Deaths in children and young people in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data

Should children be vaccinated against COVID-19 now?

Estimating the current and future prevalence of life-limiting conditions in children in England

Competing interests None declared.

Provenance and peer review Not commissioned; internally peer reviewed.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http:// creativecommons.org/licenses/by-nc/4.0/.